Glycos Biotechnologies to Report on the Company’s Malaysian Bio-refinery Project at the BIO International Convention, Washington, DC
CEO to discuss the company’s expansion plans into Malaysia and project milestones.
Washington, DC (PRWEB) June 29, 2011
Glycos Biotechnologies, Inc. (GlycosBio), an international biochemical company commercializing high-value bio-chemicals, today announced that Richard C. Cilento Jr., Chief Executive Officer, will discuss the company’s expansion plans into Malaysia including its focus on the development of isoprene, at the BIO International Convention taking place June 27th ““ 30th in Washington, DC.
GlycosBio is continuing to move forward with its expansion plans into Asia and will make a formal announcement on the selection of a lead EPC contractor in August of 2011 for its biochemical plant and biotechnology research and development facility to be located at Bio-XCell, a dedicated biotechnology park in Johor, Malaysia. Construction of the commercial plant will begin shortly thereafter with completion expected in Q4 of 2012.
The commercial facility at Bio-XCell will have the capability to produce targeted chemicals for Malaysian and Asian customers. GlycosBio will commission the facility making industrial ethanol from crude glycerin from the region. The facility’s operating flexibility will be tested using a range of feedstocks. Transition to full production will coincide with an expansion project to support the production of isoprene from low value renewable feedstocks that are readily available in Malaysia.
“Isoprene is a key building block molecule used in the production of synthetic rubber and block co-polymer products,” said Cilento. “GlycosBio is well positioned to support the Malaysian rubber industry as well the emerging regional synthetic rubber market as isoprene has a global demand of approximately 850,000 metric tons per year.”
In support of the construction of this new facility, GlycosBio has hired Mr. Rashmi Shah to lead the commissioning of the Company’s biochemical plant and biotechnology research and development facility. Serving as Vice President, Mr. Shah will be responsible for managing the construction of the Company’s bio-refinery, providing oversight, hiring a team of multinational employees and providing a local and on-site presence.
“Mr. Shah is a seasoned petrochemical expert and has significant experience leading expansion and large-scale integration projects within Southeast Asia and in other emerging regions,” said Cilento. “Rashmi’s unique background and extensive international experience will make him a tremendous asset to GlycosBio’s management team.”
About Glycos Biotechnologies, Inc.
Glycos Biotechnologies, Inc. (“GlycosBio”) is an international biochemical company commercializing advanced metabolic engineering and microbial strain processes that convert multiple low value feedstocks into a range of high value sustainable chemicals. By designing a portfolio of differentiated microorganisms, GlycosBio’s bioconversion technology produces a diverse set of chemicals, including substitutes for fossil fuel derived petrochemicals, meeting the growing global demand for clean, environmentally safe biochemicals.
GlycosBio is privately held and focused on biochemical commercialization and production with established global partnerships including relationships with petrochemical companies to secure low cost, non-petroleum based chemicals. For more information, visit http://www.glycosbio.com.
Bio-XCell is a biotechnology park and ecosystem for industrial and healthcare biotechnology, with a focus on manufacturing and R&D. Developed by Malaysian Bio-XCell Sdn Bhd, a joint venture company between BiotechCorp and UEM Land, the park is slanted to be the new regional biotech hub of Asia. Capitalising on value propositions of both its shareholders, Bio-XCell provides comprehensive infrastructure, services, incentives and benefits to drive the growth for the biotechnology sector.
Strategically located in Nusajaya, Iskandar Malaysia, the resource-rich state of Johor, Bio-XCell provides global connectivity through the network of five seaports and two international airports, all within 59kms. For information please visit http://www.bio-xcell.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/6/prweb8609062.htm